JP5689173B2 - テガフール、ギメラシル、オテラシルカリウム含有有核錠 - Google Patents

テガフール、ギメラシル、オテラシルカリウム含有有核錠 Download PDF

Info

Publication number
JP5689173B2
JP5689173B2 JP2013516428A JP2013516428A JP5689173B2 JP 5689173 B2 JP5689173 B2 JP 5689173B2 JP 2013516428 A JP2013516428 A JP 2013516428A JP 2013516428 A JP2013516428 A JP 2013516428A JP 5689173 B2 JP5689173 B2 JP 5689173B2
Authority
JP
Japan
Prior art keywords
outer shell
dry
orally disintegrating
mass
disintegrating tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013516428A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012161240A1 (ja
Inventor
拓己 岡本
拓己 岡本
吉澤　隆
隆 吉澤
敬人 大西
敬人 大西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2013516428A priority Critical patent/JP5689173B2/ja
Publication of JPWO2012161240A1 publication Critical patent/JPWO2012161240A1/ja
Application granted granted Critical
Publication of JP5689173B2 publication Critical patent/JP5689173B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013516428A 2011-05-25 2012-05-24 テガフール、ギメラシル、オテラシルカリウム含有有核錠 Active JP5689173B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013516428A JP5689173B2 (ja) 2011-05-25 2012-05-24 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011116884 2011-05-25
JP2011116884 2011-05-25
PCT/JP2012/063260 WO2012161240A1 (ja) 2011-05-25 2012-05-24 テガフール、ギメラシル、オテラシルカリウム含有有核錠
JP2013516428A JP5689173B2 (ja) 2011-05-25 2012-05-24 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014167814A Division JP5769853B2 (ja) 2011-05-25 2014-08-20 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Publications (2)

Publication Number Publication Date
JPWO2012161240A1 JPWO2012161240A1 (ja) 2014-07-31
JP5689173B2 true JP5689173B2 (ja) 2015-03-25

Family

ID=47217314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013516428A Active JP5689173B2 (ja) 2011-05-25 2012-05-24 テガフール、ギメラシル、オテラシルカリウム含有有核錠
JP2014167814A Active JP5769853B2 (ja) 2011-05-25 2014-08-20 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014167814A Active JP5769853B2 (ja) 2011-05-25 2014-08-20 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Country Status (16)

Country Link
US (1) US20140335174A1 (enExample)
EP (1) EP2716290B1 (enExample)
JP (2) JP5689173B2 (enExample)
KR (2) KR101869127B1 (enExample)
AU (1) AU2012259803B2 (enExample)
BR (1) BR112013030093B1 (enExample)
CA (1) CA2836865C (enExample)
ES (1) ES2671926T3 (enExample)
IL (1) IL229372B (enExample)
MX (1) MX353289B (enExample)
MY (1) MY167883A (enExample)
PH (1) PH12013502323A1 (enExample)
RU (1) RU2601620C2 (enExample)
SG (2) SG10201505503WA (enExample)
TW (2) TWI488659B (enExample)
WO (1) WO2012161240A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014218523A (ja) * 2011-05-25 2014-11-20 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107837273A (zh) * 2016-09-18 2018-03-27 江苏金甙生物技术有限公司 一种肠溶替吉奥缓释制剂及其制备方法
CN107865871B (zh) * 2016-09-23 2021-09-03 江苏恒瑞医药股份有限公司 一种替吉奥组合物及其制备方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
AU2020347662B2 (en) * 2019-09-13 2026-07-09 Meiji Co., Ltd. Solid food and solid milk
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
CN1660105A (zh) * 2004-12-23 2005-08-31 鲁南制药股份有限公司 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
CN101380327A (zh) * 2008-10-09 2009-03-11 北京恒瑞康达医药科技发展有限公司 抗癌复合缓释组合物及制备
CN101711765A (zh) * 2009-10-31 2010-05-26 山东新时代药业有限公司 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片
CN102614183A (zh) * 2012-03-05 2012-08-01 齐鲁制药(海南)有限公司 一种替吉奥的口服制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2087540C (en) 1991-05-27 1999-01-19 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
EP1058538B9 (en) * 1998-03-06 2013-01-02 Aptalis Pharma S.r.l. Fast disintegrating tablets
JP5178982B2 (ja) * 2000-05-18 2013-04-10 セリックス， インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US9611227B2 (en) * 2003-03-14 2017-04-04 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator and antitumor agent
WO2005030177A2 (en) * 2003-09-29 2005-04-07 Cipla Limited Pharmaceutical formulation with improved stability
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
JP5356255B2 (ja) * 2007-12-27 2013-12-04 大鵬薬品工業株式会社 経口粉粒状抗腫瘍剤
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
KR100934876B1 (ko) 2008-01-31 2010-01-06 성균관대학교산학협력단 Ｌｉｇａ공정의 도금방법
JP5553522B2 (ja) 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
EP2431032A4 (en) * 2009-05-12 2012-11-07 Taiho Pharmaceutical Co Ltd ANTICROBIAL AGENTS WITH A TEGAFUR GIMERACIL OTERACIL CALIUM COMBINATION AND OXALIPLATIN
WO2012161240A1 (ja) * 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
CN1660105A (zh) * 2004-12-23 2005-08-31 鲁南制药股份有限公司 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
CN101380327A (zh) * 2008-10-09 2009-03-11 北京恒瑞康达医药科技发展有限公司 抗癌复合缓释组合物及制备
CN101711765A (zh) * 2009-10-31 2010-05-26 山东新时代药业有限公司 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片
CN102614183A (zh) * 2012-03-05 2012-08-01 齐鲁制药(海南)有限公司 一种替吉奥的口服制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009059683; 池田和正，他: '抗腫瘍剤「ティーエスワン」の薬理作用と体内動態' 化学療法の領域 Ｖｏｌ．１７，　Ｎｏ．７, 2001, Ｐａｇｅｓ　１３１８-１３３１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014218523A (ja) * 2011-05-25 2014-11-20 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠

Also Published As

Publication number Publication date
MY167883A (en) 2018-09-26
AU2012259803B2 (en) 2016-03-17
MX353289B (es) 2018-01-05
EP2716290A1 (en) 2014-04-09
SG10201505503WA (en) 2015-09-29
KR20140037879A (ko) 2014-03-27
TW201529100A (zh) 2015-08-01
WO2012161240A1 (ja) 2012-11-29
IL229372B (en) 2018-12-31
IL229372A0 (en) 2014-01-30
NZ617625A (en) 2015-10-30
KR20170072959A (ko) 2017-06-27
JP5769853B2 (ja) 2015-08-26
BR112013030093B1 (pt) 2019-12-10
CA2836865A1 (en) 2012-11-29
US20140335174A1 (en) 2014-11-13
JPWO2012161240A1 (ja) 2014-07-31
TWI566787B (zh) 2017-01-21
EP2716290B1 (en) 2018-03-14
MX2013013563A (es) 2013-12-16
PH12013502323A1 (en) 2014-01-06
CA2836865C (en) 2018-02-27
JP2014218523A (ja) 2014-11-20
SG194922A1 (en) 2013-12-30
TW201300141A (zh) 2013-01-01
KR101869127B1 (ko) 2018-06-19
RU2601620C2 (ru) 2016-11-10
RU2013157528A (ru) 2015-06-27
TWI488659B (zh) 2015-06-21
BR112013030093A2 (pt) 2016-09-20
EP2716290A4 (en) 2014-11-26
ES2671926T3 (es) 2018-06-11

Similar Documents

Publication Publication Date Title
US9107837B2 (en) Sustained release formulation of naltrexone
CA2754853C (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP5769853B2 (ja) テガフール、ギメラシル、オテラシルカリウム含有有核錠
US20100233278A1 (en) Rapidly disintegrating solid preparation
EP3626236A1 (en) Sustained release formulation of naltrexone
EP4274557A1 (en) Oral administration of ketamine
CN102895212B (zh) 含有替加氟、吉美拉西、氧嗪酸钾的干压包衣片
HK1180584B (en) Dry pressure coated tablet containing tegafur, gimeracil, oteracil potassium
NZ617625B2 (en) Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
WO2016015797A1 (en) Water dispersible mini-tablets comprising enalapril for the treatment of hypertension in a pediatric population and method of preparation thereof
JP2025074404A (ja) マシテンタンを含有する錠剤
Swamy Journal of Advanced Pharmaceutical Sciences

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140815

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140815

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150127

R150 Certificate of patent or registration of utility model

Ref document number: 5689173

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250